Wall Street brokerages expect Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) to announce ($0.17) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Aevi Genomic Medicine’s earnings, with estimates ranging from ($0.18) to ($0.15). Aevi Genomic Medicine posted earnings per share of ($0.22) during the same quarter last year, which indicates a positive year-over-year growth rate of 22.7%. The company is expected to report its next quarterly earnings results on Thursday, March 8th.
According to Zacks, analysts expect that Aevi Genomic Medicine will report full year earnings of ($0.88) per share for the current financial year, with EPS estimates ranging from ($0.91) to ($0.85). For the next financial year, analysts expect that the business will report earnings of ($0.81) per share, with EPS estimates ranging from ($0.90) to ($0.71). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.01). During the same period in the previous year, the company earned ($0.29) earnings per share.
In other Aevi Genomic Medicine news, insider Garry Arthur Neil acquired 75,000 shares of the firm’s stock in a transaction on Tuesday, October 17th. The stock was bought at an average cost of $1.26 per share, for a total transaction of $94,500.00. Following the completion of the purchase, the insider now directly owns 114,774 shares in the company, valued at $144,615.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sol J. Barer acquired 421,032 shares of the firm’s stock in a transaction on Tuesday, October 17th. The shares were acquired at an average price of $1.26 per share, with a total value of $530,500.32. Following the completion of the purchase, the director now owns 1,028,032 shares of the company’s stock, valued at $1,295,320.32. The disclosure for this purchase can be found here. In the last three months, insiders bought 615,079 shares of company stock valued at $775,000. Company insiders own 15.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. LMR Partners LLP acquired a new stake in shares of Aevi Genomic Medicine during the second quarter worth $149,000. Wells Fargo & Company MN raised its position in Aevi Genomic Medicine by 433.7% during the third quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 106,178 shares in the last quarter. Northern Capital Management LLC raised its position in shares of Aevi Genomic Medicine by 317.9% in the second quarter. Northern Capital Management LLC now owns 106,050 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 80,675 shares during the period. Birchview Capital LP grew its stake in shares of Aevi Genomic Medicine by 88.2% in the second quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 60,000 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in shares of Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 13,966 shares during the last quarter. Hedge funds and other institutional investors own 16.90% of the company’s stock.
Shares of Aevi Genomic Medicine (NASDAQ:GNMX) opened at $1.18 on Friday. Aevi Genomic Medicine has a twelve month low of $0.98 and a twelve month high of $6.89.
WARNING: “-$0.17 EPS Expected for Aevi Genomic Medicine, Inc. (GNMX) This Quarter” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/10/0-17-eps-expected-for-aevi-genomic-medicine-inc-gnmx-this-quarter.html.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.